ProCE Banner Activity

CE / CME

Guideline-Endorsed Answers to Key Questions in Nontuberculous Mycobacterial Lung Disease Management

Hear insights from 3 faculty experts as they engage in a lively discussion on guideline updates in the diagnosis, monitoring, and treatment of patients with nontuberculous mycobacterial lung disease.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: November 19, 2021

Expiration: November 18, 2022

No longer available for credit.

Share

Faculty

Keira A. Cohen

Keira A. Cohen, MD

Assistant Professor of Medicine
Pulmonary and Critical Care Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

David E. Griffith

David E. Griffith, MD

Professor of Medicine
Division of Mycobacterial and Respiratory Infections
Department of Medicine
National Jewish Hospital
Denver, Colorado

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Insmed Incorporated

Partners

NTMIR

ProCE Banner

Target Audience

This program is intended for infectious disease and pulmonology physicians, pharmacists, and other healthcare professionals who care for patients with NTM-LD.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Utilize appropriate clinical, radiographic, and microbiologic criteria for reducing time to NTM-LD diagnosis and characterization
  • Develop guideline-recommended and evidence-based approaches to the treatment of NTM-LD
  • Identify key issues of importance to patients surrounding their illness symptoms and treatment adverse events
  • In partnership with patients, provide individualized and comprehensive treatment plans for NTM-LD

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Keira A. Cohen, MD

Assistant Professor of Medicine
Pulmonary and Critical Care Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Keira A. Cohen, MD, has disclosed that she has received consulting fees from HillRom, Insmed, and Microbion and fees for non-CME/CE services from Insmed.

Faculty Disclosure

Primary Author

David E. Griffith, MD

Professor of Medicine
Division of Mycobacterial and Respiratory Infections
Department of Medicine
National Jewish Hospital
Denver, Colorado

David E. Griffith, MD, has disclosed that he has received funds for research support from Insmed, consulting fees from AN2 Therapeutics and Insmed, and fees for non-CME/CE services from Insmed.

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP, has disclosed that she has received funds for research support from Amgen, Gilead Sciences, GlaxoSmithKline, and Merck; has received consulting fees from Amgen, GlaxoSmithKline, and Merck; and has ownership interests in Gilead Sciences, Johnson & Johnson, Merck, and Pfizer.

Staff Disclosure

Staff

Sarah Anderson, PharmD

Scientific Director

Sarah L. Anderson, PharmD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-251-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 19, 2021, through November 18, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of learners to apply practice guidelines and provide patient-centered care in the diagnosis and management of NTM-LD.